(Q37786424)

23 August 2017

title

Applications of nanoparticles in ophthalmology (English)

1 reference

23 August 2017

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20826225

9 July 2024

2

Margarita Calonge

1 reference

23 August 2017

Yolanda Diebold

1

0 references

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20826225

9 July 2024

publication date

6 September 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S1350946210000558?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

https://api.elsevier.com/content/article/PII:S1350946210000558?httpAccept=text/plain

9 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Progress in Retinal and Eye Research

9 July 2024

published in

1 reference

23 August 2017

volume

29

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

596-609

1 reference

Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy

23 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

pH-dependent disruption of erythrocyte membrane by amphiphilic poly(amino acid) nanoparticles.

9 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

The potential of chitosan in ocular drug delivery.

9 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea

9 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Endocytic mechanisms for targeted drug delivery

9 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations

9 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Immune response following intraocular delivery of recombinant viral vectors

9 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Non-viral ocular gene therapy: potential ocular therapeutic avenues.

9 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Recent developments in ocular gene therapy

9 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Gene therapy for glaucoma: treating a multifaceted, chronic disease

9 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles.

9 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Effect of gene therapy on visual function in Leber's congenital amaurosis

9 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

RNAi therapeutics: a potential new class of pharmaceutical drugs

9 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A

9 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Gene therapy for retinal and choroidal diseases

9 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders

9 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics

9 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides

9 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Controlled delivery of biotechnological products

9 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Ocular tolerance to a topical formulation of hyaluronic acid and chitosan-based nanoparticles.

9 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Nanocapsules: A new type of lysosomotropic carrier

9 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord neurons

9 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity

9 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A.

9 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa.

9 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Novel hyaluronan-based nanocarriers for transmucosal delivery of macromolecules.

9 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy.

9 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Current and future ophthalmic drug delivery systems. A shift to the posterior segment.

9 July 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells.

9 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP).

9 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Ocular delivery of compacted DNA-nanoparticles does not elicit toxicity in the mouse retina

9 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution

9 July 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Immunological properties of engineered nanomaterials

9 July 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Controlled delivery of peptides and proteins

9 July 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Predicted permeability of the cornea to topical drugs

9 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance.

9 July 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Efficient non-viral ocular gene transfer with compacted DNA nanoparticles

9 July 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.

9 July 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.

9 July 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Ultrasound mediated delivery of drugs and genes to solid tumors

9 July 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Recent perspectives in ocular drug delivery

9 July 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Transscleral drug delivery for posterior segment disease

9 July 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Biodegradable long-circulating polymeric nanospheres

9 July 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy

9 July 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Antiangiogenic properties of silver nanoparticles

9 July 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

The role of cerium redox state in the SOD mimetic activity of nanoceria.

9 July 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera

9 July 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Nanoparticle-cell interactions: drug delivery implications

9 July 2024

52

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Subretinal delivery of immunoglobulin G with gold nanoparticles in the rabbit eye.

9 July 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Specific regulation of gene expression by antisense, sense and antigene nucleic acids

9 July 2024

54

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides

9 July 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Progress and prospects: naked DNA gene transfer and therapy

9 July 2024

56

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Nanocarriers' entry into the cell: relevance to drug delivery

9 July 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Preparation of controlled release ophthalmic drops, for glaucoma therapy using thermosensitive poly-N-isopropylacrylamide.

9 July 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs

9 July 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and cornea

9 July 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat

9 July 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Nonviral ocular gene transfer.

9 July 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Characterization of pilocarpine-loaded chitosan/Carbopol nanoparticles

9 July 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.

9 July 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Ocular preparations: the formulation approach

9 July 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Limits on optimizing ocular drug delivery.

9 July 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Formulation of chitosan-DNA nanoparticles with poly(propyl acrylic acid) enhances gene expression.

9 July 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Intravenously administered gold nanoparticles pass through the blood-retinal barrier depending on the particle size, and induce no retinal toxicity

9 July 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Smaller is not always better: nanotechnology yields nanotoxicology

9 July 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Ultrapure chitosan oligomers as carriers for corneal gene transfer

9 July 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

RNA interference: from gene silencing to gene-specific therapeutics

9 July 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Nanotechnology and aptamers: applications in drug delivery

9 July 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Ocular drug delivery of progesterone using nanoparticles

9 July 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Characterization of oligonucleotide transport into living cells

9 July 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol

9 July 2024

76

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Improvement of ocular penetration of amikacin sulphate by association to poly(butylcyanoacrylate) nanoparticles

9 July 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Nanoparticles target distinct dendritic cell populations according to their size

9 July 2024

78

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics

9 July 2024

79

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Gene delivery to the eye using adeno-associated viral vectors

9 July 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Nanotechnology for the biologist

9 July 2024

81

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Nanoparticles: pharmacological and toxicological significance

9 July 2024

82

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties.

9 July 2024

83

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Efficacy of ganciclovir-loaded nanoparticles in human cytomegalovirus (HCMV)-infected cells

9 July 2024

84

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene

9 July 2024

85

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Aptamers: an emerging class of therapeutics

9 July 2024

89

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo

9 July 2024

90

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Particle formation by a conserved domain of the herpes simplex virus protein VP22 facilitating protein and nucleic acid delivery

9 July 2024

91

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Perspectives on gene therapy in the treatment of ocular inflammation

9 July 2024

92

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Single-walled and multi-walled carbon nanotubes promote allergic immune responses in mice

9 July 2024

93

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Gold nanoparticles enable selective light-induced contents release from liposomes

9 July 2024

94

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

An artificial nano-drainage implant (ANDI) for glaucoma treatment.

9 July 2024

95

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Single walled carbon nanotube reactivity and cytotoxicity following extended aqueous exposure

9 July 2024

96

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Chitosan nanoparticles for drug delivery to the eye.

9 July 2024

97

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage

9 July 2024

98

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Vitreous: a barrier to nonviral ocular gene therapy

9 July 2024

99

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Nanoceria have no genotoxic effect on human lens epithelial cells

9 July 2024

100

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen

9 July 2024

101

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles.

9 July 2024

102

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Aptamers--basic research, drug development, and clinical applications

9 July 2024

103

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Assessing immunotoxicity: guidelines

9 July 2024

105

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Clathrin and caveolin-1 expression in primary pigmented rabbit conjunctival epithelial cells: role in PLGA nanoparticle endocytosis

9 July 2024

106

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

The number of people with glaucoma worldwide in 2010 and 2020

9 July 2024

107

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Adeno-associated virus expression systems for gene transfer

9 July 2024

108

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Gene therapy for neurodegenerative and ocular diseases using lentiviral vectors

9 July 2024

109

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Exploiting lymphatic transport and complement activation in nanoparticle vaccines

9 July 2024

110

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Ocular gene therapy: an evaluation of recombinant adeno-associated virus-mediated gene therapy interventions for the treatment of ocular disease

9 July 2024

111

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Nanotechnology in ocular drug delivery

9 July 2024

113

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

The present and future of nanotechnology in human health care

9 July 2024

114

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate

9 July 2024

115

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Ocular drug delivery. Pharmacokinetic considerations

9 July 2024

118

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Regulatory immunotoxicology: does the published evidence support mandatory nonclinical immune function screening in drug development?

9 July 2024

119

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Biodegradable polymeric nanoparticles as drug delivery devices

9 July 2024

121

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Development of in vitro systems for nanotoxicology: methodological considerations

9 July 2024

122

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles

9 July 2024

123

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Vacancy engineered ceria nanostructures for protection from radiation-induced cellular damage.

9 July 2024

124

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Controlled gene gun delivery and expression of DNA within the cornea.

9 July 2024

125

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

A case of toxic epidermal necrolysis-like dermatitis evolving from contact dermatitis of the hands associated with exposure to dendrimers

9 July 2024

126

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Challenges and obstacles of ocular pharmacokinetics and drug delivery

9 July 2024

127

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Ocular drug delivery: nanomedicine applications

9 July 2024

128

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration

9 July 2024

129

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation

9 July 2024

130

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Permeability and diffusion in vitreous humor: implications for drug delivery

9 July 2024

132

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Visualizing vitreous using quantum dots as imaging agents

9 July 2024

133

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Titanium dioxide nanoparticles aggravate atopic dermatitis-like skin lesions in NC/Nga mice

9 July 2024

134

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Size effects of polystyrene nanoparticles on atopic dermatitislike skin lesions in NC/NGA mice

9 July 2024

135

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea.

9 July 2024

136

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

VP22-mediated and light-activated delivery of an anti-c-raf1 antisense oligonucleotide improves its activity after intratumoral injection in nude mice.

9 July 2024

137

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Development of new drugs in angiogenesis

9 July 2024

138

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Studies on the transport pathway of PBCA nanoparticles in ocular tissues

9 July 2024

139

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Pharmacokinetic and pharmacodynamic aspects of an ophthalmic pilocarpine nanoparticle-delivery-system

9 July 2024

140

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

Nanoparticles and the immune system

9 July 2024

141

1 reference

https://api.crossref.org/works/10.1016/J.PRETEYERES.2010.08.002

9 July 2024

Identifiers

1 reference

23 August 2017

1 reference